About Biomoda
Biomoda is a cancer diagnostics company focused on the development of an inexpensive, simple, highly accurate in-vitro test for the early detection of lung cancer. The CyPath® assay is based upon Biomoda’s patent estate centered on molecular marker technology originally developed at the Los Alamos National Laboratory.
Biomoda trades under the symbol BMOD (OTC Bulletin Board) and files regular reports with the U.S. Securities and Exchange Commission (SEC), available on the SEC’s EDGAR site. Current research and development operations, laboratory functions for both microscopy and assay formulation, and administrative offices are located at 609 Broadway NE in Albuquerque, NM, in a LEEDS-certified building.
In recent years, lung cancer has become the leading cause of cancer deaths worldwide with 1.2 million new cases reported annually. More than 170,000 Americans are diagnosed with the disease each year, and despite research efforts the prognosis is still poor. According to the International Association for the Study of Lung Cancer, in two-thirds of lung cancer patients, the cancer has spread to regional lymph nodes or beyond at the time of initial diagnosis, resulting in a dismal five-year survival rate of only 15%. Early detection increases the survival rate to approximately 92%, according to an I-ELCAP study published in the New England Journal of Medicine.
The Biomoda technology directly addresses a global health crisis by making the early diagnosis of the deadliest cancers available at an affordable cost to large populations worldwide.
Biomoda is seeking U.S. Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device under the Pre-Market Approval (PMA) process. Pending FDA approval of the initial assay for detection of early-stage lung cancer, Biomoda expects its products to find rapid, broad acceptance in the marketplace by offering high sensitivity and accuracy at the cellular level, simple noninvasive use and very affordable cost.
Future product and market extensions will focus on the diagnosis, screening and monitoring of other cancers. Assays for cervical, breast, colorectal, bladder, circulating tumor cell (CTC) and oral cancers are targeted for development.